You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Medtronic
Mallinckrodt
Boehringer Ingelheim
Harvard Business School

Last Updated: April 14, 2021

DrugPatentWatch Database Preview

Patent: 10,258,619

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,258,619
Title:Combination therapy with glutaminase inhibitors and immuno-oncology agents
Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Inventor(s): Molineaux; Susan M. (San Francisco, CA), Gross; Matthew I. (San Francisco, CA), Bromley; Susan D. (San Francisco, CA), Parlati; Francesco (San Francisco, CA), Bennett; Mark K. (Moraga, CA)
Assignee: Calithera Biosciences, Inc. (South San Francisco, CA)
Application Number:15/284,865
Patent Claims:see list of patent claims

Details for Patent 10,258,619

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2035-10-05 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2035-10-05 RX search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2035-10-05 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2035-10-05 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2035-10-05 RX Orphan search
Novartis ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2035-10-05 RX search
Novartis KESIMPTA ofatumumab SOLUTION;SUBCUTANEOUS 125326 002 2009-10-26   Start Trial Calithera Biosciences, Inc. (South San Francisco, CA) 2035-10-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKinsey
Boehringer Ingelheim
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.